Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 855 prophylaxis versus on-demand treatment in previously treated patients with severe hemophilia A
2012-003599-38Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of recombinant human coagulation factor VIII in hemophilia A (2 arms), sponsored by Baxter International Inc. Primary endpoint: Annualized bleeding rate ratio between prophylaxis and on-demand treatment. Started Dec 2012; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-003599-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003599-38.